



**MOTHER & CHILD**  
GROUP OF COMPANIES

## **MD MEDICAL GROUP ANNOUNCES THE LAUNCH OF LAPINO-4**

**1 February 2021, Moscow** – MD Medical Group Investments Plc ("MD Medical Group", "MDMG" or the "Company" – MDMG), a leading Russian private healthcare provider announces the launch of a new multifunctional medical centre ("Lapino-4") on the Lapino medical complex grounds.

The construction of the new 2-storey multifunctional medical centre intended to treat patients with infections, including coronavirus patients, was achieved in short time using rapid construction technology. The centre has a total area of 4200 sq. metres.

The centre will provide highly professional medical care, including patients with surgical pathology complicated by COVID-19 and maternity patients.

The centre will have 100 beds, including 12 in the emergency room. All wards are fitted with equipment to provide patients with oxygen. A CT department is in place.

Logistics outside and inside the building were carefully planned in order to guarantee an efficient and safe flow of patients. Lapino-4, which is located on the new grounds of the Lapino medical complex, has a separate entry point.

Cumulative investment in the project amounts to 800 million rubles. Around 130 new jobs will be created. Treatment of patients will be done under the VHI and MHI programs as well.

Lapino-4 has been created in line with MD Medical Group's customary high standards of medical care and is fitted with world-class equipment produced by GE, Hamilton, B.Braun, Olympus.

**Mark Kurtser, CEO of MD Medical Group, said:** "We continue to expand the Lapino medical complex in line with the Company's strategic course to diversify the scope of medical services provided to our patients. After the launch of Lapino-4, we will be able to resume at full strength the work of our new multidisciplinary oncology service which returns to operate at the "Lapino-2" hospital."

**For further information please contact:**

**Investors**

**Dmitry Yakushkin**

MD Medical Group Investments Plc

Tel: +7 (495) 139-87-40, ext. 16329

[d.yakushkin@mcclinics.ru](mailto:d.yakushkin@mcclinics.ru)

**Media**

**EM**

Tom Blackwell: +7 919 102 9064

Sergii Pershyn: +1 929 855 8188

[MDMG@em-comms.com](mailto:MDMG@em-comms.com)

**About MD Medical Group**

MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 42 modern healthcare facilities, including 6 hospitals and 36 out-patient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, Nizhny Novgorod, Volgograd, Tula, Kazan, Vladivostok, Krasnodar and Rostov-on-Don.

The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.

Since November 9, 2020 the Company's GDRs are traded also on the Moscow Exchange. Quotation is done in Russian Rubles.

**Forward-Looking Statements:**

This press release contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.